teriflunomide HMR1726 vs vidofludimus calcium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: Dihydroorotate dehydrogenase (DHODH) · full Multiple Sclerosis pipeline

teriflunomide HMR1726 · Aubagio

Marketed by Sanofi

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT03122652 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled trial of 125 participants met its primary endpoint: teriflunomide reduced the risk of a first clinical demyelinating event by about 63 to 72% compared with placebo, a statistically significant result.

Reported efficacy

Time to the first acute or progressive neurological event resulting from CNS demyelination. (Week 96): Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction) (met)

Result source: NCT03122652

vidofludimus calcium

Developed by Immunic, Inc.

Phase 3 in Multiple Sclerosis
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT05201638 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointteriflunomide HMR1726vidofludimus calcium
Annualised relapse rate—Not posted · NCT01863888—Trial running · NCT05201638
Free of 3-month confirmed disability progression (%)—Not posted · NCT01863888—Trial running · NCT05201638
New or enlarging T2 lesions—Not posted · NCT01863888—Trial running · NCT05201638

Annualised relapse rate

teriflunomide HMR1726
—Not posted · NCT01863888
vidofludimus calcium
—Trial running · NCT05201638

Free of 3-month confirmed disability progression (%)

teriflunomide HMR1726
—Not posted · NCT01863888
vidofludimus calcium
—Trial running · NCT05201638

New or enlarging T2 lesions

teriflunomide HMR1726
—Not posted · NCT01863888
vidofludimus calcium
—Trial running · NCT05201638
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

vidofludimus calcium: no structured comparison results are available for Multiple Sclerosis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

teriflunomide HMR1726
Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction) NCT03122652 · Phase 3 · design grade: strong · publication or press release
Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results). NCT00751881 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: teriflunomide HMR1726's landscape · vidofludimus calcium's landscape